[go: up one dir, main page]

SG194725A1 - Rapid dissolve tablet compositions for vaginal administration - Google Patents

Rapid dissolve tablet compositions for vaginal administration Download PDF

Info

Publication number
SG194725A1
SG194725A1 SG2013080882A SG2013080882A SG194725A1 SG 194725 A1 SG194725 A1 SG 194725A1 SG 2013080882 A SG2013080882 A SG 2013080882A SG 2013080882 A SG2013080882 A SG 2013080882A SG 194725 A1 SG194725 A1 SG 194725A1
Authority
SG
Singapore
Prior art keywords
compositions
ingredients suitable
active pharmaceutical
rapid dissolve
administration
Prior art date
Application number
SG2013080882A
Inventor
Gopi Venkatesh
Vijaya Swaminathan
Jin-Wang Lai
Original Assignee
Aptalis Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptalis Pharmatech Inc filed Critical Aptalis Pharmatech Inc
Publication of SG194725A1 publication Critical patent/SG194725A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)

Abstract

Disclosed herein are pharmaceutically acceptable rapid dissolve vaginal tablet compositions comprising one or more active pharmaceutical ingredients suitable for therapy via topical action or systemic absorption, and methods of making and using such compositions. In some embodiments, this invention relates to pharmaceutical compositions comprising one or more active pharmaceutical ingredients suitable for vaginal route of administration, and methods of making and using such compositions for therapy via topical action or systemic absorption, as well as uterine targeting. In certain embodiments, the present invention is related to a pharmaceutical composition comprising one or more active pharmaceutical ingredients suitable for vaginal route of administration, one or more polymeric excipients having a dual property of acting as a binder as well as a bioadhesive material, one or more sugar alcohols or saccharides, and one or more disintegrants.
SG2013080882A 2011-05-02 2012-05-02 Rapid dissolve tablet compositions for vaginal administration SG194725A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481582P 2011-05-02 2011-05-02
PCT/US2012/036055 WO2012151237A1 (en) 2011-05-02 2012-05-02 Rapid dissolve tablet compositions for vaginal administration

Publications (1)

Publication Number Publication Date
SG194725A1 true SG194725A1 (en) 2013-12-30

Family

ID=47108022

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013080882A SG194725A1 (en) 2011-05-02 2012-05-02 Rapid dissolve tablet compositions for vaginal administration

Country Status (16)

Country Link
EP (1) EP2704694A4 (en)
JP (1) JP6154803B2 (en)
KR (2) KR20160112012A (en)
CN (1) CN103596556A (en)
AP (1) AP2013007268A0 (en)
AR (1) AR086249A1 (en)
AU (1) AU2012250862B2 (en)
CA (1) CA2839790A1 (en)
CL (1) CL2013003161A1 (en)
CO (1) CO6940408A2 (en)
IL (1) IL229170A0 (en)
MX (1) MX2013012745A (en)
RU (1) RU2013150323A (en)
SG (1) SG194725A1 (en)
TW (1) TW201247240A (en)
WO (1) WO2012151237A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187984A1 (en) 2012-06-13 2013-12-19 Evofem, Inc. Compositions and methods for enhancing the efficacy of contraceptive microbicides
CA2906642A1 (en) * 2013-03-15 2014-09-18 Conrad Low-glycerin formulations for hiv treatment and prevention
WO2015070072A1 (en) * 2013-11-07 2015-05-14 Evofem, Inc. Methods for manufacturing contraceptive microbicides with antiviral properties
NZ722215A (en) * 2013-12-19 2019-02-22 Evofem Inc Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
CN110179801B (en) * 2014-04-11 2021-08-06 上海宣泰医药科技股份有限公司 Posaconazole medicine composition, preparation method and medicine preparation thereof
CA2956723C (en) 2014-08-12 2023-04-11 Nextgen Jane, Inc. System and method for monitoring health based on collected bodily fluid
CN104434992B (en) * 2014-12-21 2018-06-08 昆明赛诺制药股份有限公司 A kind of American-cockroach-extract bioadhesive vaginal tablets and preparation method thereof
CA2988082C (en) 2015-06-01 2020-09-29 Symbiomix Therapeutics, Llc Novel nitroimidazole formulations and uses thereof
EP3442706B1 (en) 2016-04-13 2025-07-23 NextGen Jane, Inc. Sample collection and preservation methods
AU2017338748A1 (en) 2016-10-04 2019-05-02 Evofem Inc. Method of treatment and prevention of bacterial vaginosis
JP7219712B2 (en) * 2016-10-13 2023-02-08 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド Lyophilized pharmaceutical composition for vaginal delivery
ES3017694T3 (en) 2017-10-06 2025-05-13 Gedea Biotech Ab Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MX2021004553A (en) 2018-10-23 2021-07-16 Eastern Virginia Medical School Pharmaceutical compositions and methods of making on demand solid dosage formulations.
WO2020128525A1 (en) * 2018-12-21 2020-06-25 The University Of Liverpool Nrti therapies
KR102357795B1 (en) * 2019-04-19 2022-02-04 한양대학교 산학협력단 Thermosensitive composition comprising phosphatidic acid and the use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US6899890B2 (en) 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US20040228932A1 (en) * 2003-05-12 2004-11-18 Pilgaonkar Pratibha S. Pharmaceutical excipient
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
JP2006022039A (en) * 2004-07-08 2006-01-26 Towa Yakuhin Kk Simvastatin solid preparation having high stability
UA93354C2 (en) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Topical antiviral formulations
CN1257715C (en) * 2004-08-02 2006-05-31 程月发 Clindamycin metronidazole vagina effervescent tablet and its preparing method and use
WO2006082596A2 (en) 2005-01-19 2006-08-10 Kamalinder Kaur Singh Neem oil contraceptive formulations
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
CN1970079A (en) * 2006-12-08 2007-05-30 陕西沃普森制药有限公司 Vagina effervescence tablet of recombinant human interferon alpha-2a and preparation process thereof
PL2656879T3 (en) * 2006-12-10 2017-09-29 Chongxi Yu Transdermal delivery systems of beta-lactam antibiotics
EP2146698A2 (en) * 2007-05-24 2010-01-27 New York Blood Center, Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
US20090169620A1 (en) * 2007-12-21 2009-07-02 Venkatesh Gopi M Orally disintegrating tablet compositions of temazepam
CN101283989A (en) * 2008-02-28 2008-10-15 何文健 Metronidazole vaginal tablet process and quality control method
CN101406463B (en) * 2008-02-28 2012-04-25 陕西君碧莎制药有限公司 Metronidazole, clotrimazole and chlorhexidine acetate vaginal effervescent tablet and preparation method thereof
RU2519715C2 (en) * 2008-10-23 2014-06-20 Хенкель Корпорейшн Pharmaceutical granules, containing modified starch, and their therapeutic applications
CN101780203B (en) * 2010-03-16 2012-09-05 刘仁杰 Lubrication effervescent agent for yin nourishing, nest warming, body deodorizing and youth keeping and preparation method thereof

Also Published As

Publication number Publication date
TW201247240A (en) 2012-12-01
AU2012250862B2 (en) 2015-07-09
KR20140014264A (en) 2014-02-05
JP6154803B2 (en) 2017-06-28
NZ617376A (en) 2016-03-31
RU2013150323A (en) 2015-06-10
CN103596556A (en) 2014-02-19
AU2012250862A1 (en) 2013-05-02
AP2013007268A0 (en) 2013-11-30
CO6940408A2 (en) 2014-05-09
MX2013012745A (en) 2014-12-05
EP2704694A1 (en) 2014-03-12
AR086249A1 (en) 2013-11-27
EP2704694A4 (en) 2014-11-19
CA2839790A1 (en) 2012-11-08
IL229170A0 (en) 2013-12-31
JP2014513124A (en) 2014-05-29
WO2012151237A1 (en) 2012-11-08
KR20160112012A (en) 2016-09-27
CL2013003161A1 (en) 2014-08-01

Similar Documents

Publication Publication Date Title
SG194725A1 (en) Rapid dissolve tablet compositions for vaginal administration
NZ611467A (en) Rapidly dispersing granules, orally disintegrating tablets and methods
PH12014502516A1 (en) Formulations and methods for vaginal delivery of antiprogestins
CL2016001411A1 (en) Solid pharmaceutical dosage unit of oral disintegration comprising an estetrol component; Preparation method; use for female contraception and in female hormone replacement therapy.
WO2013183062A3 (en) Palatable formulations of ibuprofen
BR112012007412A2 (en) orally transformable tablets.
WO2009006095A3 (en) Dual portion lozenge dosage form
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
MX2012003082A (en) Pharmaceutical compositions for reducing alcohol-induced dose dumping.
DOP2011000354A (en) SUBLINGUAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
MX2010006284A (en) Phenylephrine pharmaceutical formulations and compositions for transmucosal absorption.
UA116334C2 (en) SOLID FORMS OF BENDAMUSTINE DOSAGE
MX2014008284A (en) FORMULATION OF DELAYED RELEASE TO REDUCE THE FREQUENCY OF URINATING AND METHODS OF USE OF THIS.
MX2014008283A (en) FORMULATION OF PROLONGED RELEASE TO REDUCE THE FREQUENCY OF URINATING AND METHODS OF USE OF THIS.
TR200900878A2 (en) Pharmaceutical formulations combined in a single dosage form
MX362485B (en) Novel rock inhibitors.
MY174090A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
TN2015000135A1 (en) Modified release formulations for oprozomib
HK1214519A1 (en) Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof
WO2011064558A3 (en) Pharmaceutical composition
CA2863829A1 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease
PE20070430A1 (en) TOPICAL COMPOSITIONS INCLUDING O-DESMETILVENLAFAXINE (ODV)
TR200900880A2 (en) Pharmaceutical compositions combined in a single dosage form.
TN2015000156A1 (en) Dispersible tablet
PH22011000655U1 (en) Pharmaceutical herbal composition